Cargando…

Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability

BACKGROUND: Severe refractory asthma is a heterogeneous disease. We sought to determine statistical clusters from the British Thoracic Society Severe refractory Asthma Registry and to examine cluster-specific outcomes and stability. METHODS: Factor analysis and statistical cluster modelling was unde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Newby, Chris, Heaney, Liam G., Menzies-Gow, Andrew, Niven, Rob M., Mansur, Adel, Bucknall, Christine, Chaudhuri, Rekha, Thompson, John, Burton, Paul, Brightling, Chris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109965/ https://www.ncbi.nlm.nih.gov/pubmed/25058007 http://dx.doi.org/10.1371/journal.pone.0102987

Ejemplares similares

Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry
por: Sweeney, Joan, et al.
Publicado: (2012)

Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry
por: Heaney, Liam G, et al.
Publicado: (2010)

Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
por: Jackson, David J, et al.
Publicado: (2021)

Benefits of specialist severe asthma management: demographic and geographic disparities
por: Redmond, Charlene, et al.
Publicado: (2022)

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)
por: Heaney, Liam G, et al.
Publicado: (2016)

Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)
por: Niven, Robert M, et al.
Publicado: (2016)

Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
por: Barnes, Neil, et al.
Publicado: (2013)

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease
por: Ghebre, Michael A., et al.
Publicado: (2015)

Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma
por: Busby, John, et al.
Publicado: (2022)

Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma
por: Couillard, Simon, et al.
Publicado: (2021)

Sarcoidosis in the UK: insights from British Thoracic Society registry data
por: Thillai, Muhunthan, et al.
Publicado: (2019)

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial
por: Hanratty, Catherine E., et al.
Publicado: (2018)

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
por: Heaney, Liam G, et al.
Publicado: (2021)

Efficacy and safety of bronchial thermoplasty in clinical practice: a prospective, longitudinal, cohort study using evidence from the UK Severe Asthma Registry
por: Burn, Julie, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019
por: Spencer, Lisa G., et al.
Publicado: (2021)

Long‐term corticosteroid use, adrenal insufficiency and the need for steroid‐sparing treatment in adult severe asthma
por: Gurnell, M., et al.
Publicado: (2021)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
por: Menzies-Gow, Andrew, et al.
Publicado: (2019)

A Charter to Fundamentally Change the Role of Oral Corticosteroids in the Management of Asthma
por: Haughney, John, et al.
Publicado: (2023)

Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment
por: Mansur, Adel H.
Publicado: (2021)

International severe asthma registry (ISAR): protocol for a global registry
por: FitzGerald, J. Mark, et al.
Publicado: (2020)

Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA)
por: Lanario, Joseph W., et al.
Publicado: (2020)

Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthma
por: Hyland, Michael E, et al.
Publicado: (2021)

The Biology of Eosinophils and Their Role in Asthma
por: McBrien, Claire N., et al.
Publicado: (2017)

Difficult‐to‐treat asthma patients from ethnic minority groups in central England are at an enhanced risk of house dust mite sensitisation
por: Mansur, Adel H., et al.
Publicado: (2023)

Perceptions of asthma control in the United Kingdom: a cross-sectional study comparing patient and healthcare professionals’ perceptions of asthma control with validated ACT scores
por: Menzies-Gow, Andrew, et al.
Publicado: (2017)

The impact of the first COVID-19 surge on severe asthma patients in the UK. Which is worse: the virus or the lockdown?
por: Smith, Steven J., et al.
Publicado: (2021)

Defining severe asthma – an approach to find new therapies
por: Nanzer, Alexandra M., et al.
Publicado: (2014)

Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry
por: Kim, Min-Hye, et al.
Publicado: (2018)

Computational modeling of the obstructive lung diseases asthma and COPD
por: Burrowes, Kelly Suzanne, et al.
Publicado: (2014)

The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference
por: Masoli, Matthew, et al.
Publicado: (2021)

Severe Asthma—Perspectives From Adult and Pediatric Pulmonology
por: Fleming, Louise, et al.
Publicado: (2019)

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
por: Menzies-Gow, Andrew N, et al.
Publicado: (2022)

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
por: Piper, Edward, et al.
Publicado: (2013)

Holy Grail: the journey towards disease modification in asthma
por: Busse, William W., et al.
Publicado: (2022)

Recommendations following a modified UK-Delphi consensus study on best practice for referral and management of severe asthma
por: Jackson, David J, et al.
Publicado: (2021)

Omalizumab: Clinical Use for the Management of Asthma
por: Thomson, Neil C., et al.
Publicado: (2012)

Derivation of asthma severity from electronic prescription records using British thoracic society treatment steps
por: Tibble, Holly, et al.
Publicado: (2022)

Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker‐high and ‐low severe asthma
por: Khalfaoui, Latifa, et al.
Publicado: (2022)

British Thoracic Society Training Standards for Thoracic Ultrasound (TUS)
por: Stanton, Andrew E, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0lmiau9eo480qf6slq3hc41u44